* The use of alectinib as first line therapy for ALK positive lung cancer patients has been approved by the FDA on 6 November 2017, based on the ALEX study.
[1] A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX) NCT02075840
[2] Alectinib (ALC) vs crizotinib (CRZ) in treatment-na?ve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study? will be presented by Tony S.K. Mok during Proffered paper session 1 on Saturday, 18 November 2017, 08:30 to 10:30 (SGT) in Hall 405. Annals of Oncology, Volume 28, 2017 Supplement 10, Abstract 410O_PR.
[3] Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29?39.
[4] Peters S, Camidge R, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non?small-cell lung cancer. N Engl J Med. 2017;377:829?838.
Home The use of alectinib as first line therapy for ALK positive lung cancer patients
